Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial

Lung Cancer - Tập 178 - Trang 151-156 - 2023
Chao Lv1, Wentao Fang2, Nan Wu1, Wenjie Jiao3, Shidong Xu4, Haitao Ma5, Jia Wang1, Rui Wang6, Chunyu Ji2, Shaolei Li1, Yuzhao Wang1, Shi Yan1, Fangliang Lu1, Yuquan Pei1, Yinan Liu1, Yue Yang1
1Second Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing, China
2Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
3Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao, China
4Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, China
5Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Jiangsu, China
6Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Tài liệu tham khảo

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660

Zhang, 2021, Cancer incidence and mortality in China, 2015, J. Natl. Cancer Center, 1, 2, 10.1016/j.jncc.2020.12.001

Asamura, 2015, The International association for the study of lung cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer, J. Thorac. Oncol., 10, 1675, 10.1097/JTO.0000000000000678

NSCLC Meta-analysis Collaborative Group, 2014, Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data, Lancet, 383, 1561, 10.1016/S0140-6736(13)62159-5

Xiong, 2019, Erlotinib as neoadjuvant therapy in stage IIIA (N2) mutation-positive non-small cell lung cancer: a prospective, single-arm, phase II study, Oncologist, 24, 10.1634/theoncologist.2018-0120

Zhang, 2021, Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: a phase II study, J. Thorac. Cardiovasc. Surg., 161, 434, 10.1016/j.jtcvs.2020.02.131

Xiong, 2020, Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients, J. Int. Med. Res., 48, 10.1177/0300060519887275

Zhong, 2019, Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 -mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study, J. Clin. Oncol., 37, 2235, 10.1200/JCO.19.00075

Piper-Vallillo, 2021, FP01.05 the ASCENT trial: a phase II study of neoadjuvant/adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC, J. Thorac. Oncol., 16, S188, 10.1016/j.jtho.2021.01.072

Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N. Engl. J. Med., 378, 113, 10.1056/NEJMoa1713137

Cheng, 2021, Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study, Target Oncol., 16, 165, 10.1007/s11523-021-00794-6

Wu, 2020, Osimertinib in resected EGFR-mutated non-small-cell lung cancer, N. Engl. J. Med., 383, 1711, 10.1056/NEJMoa2027071

Chen, 2021, Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report, J. Med. Case Rep., 15, 216, 10.1186/s13256-021-02748-y

Amin, 2017

Zhu, 2018, A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma, Oncol. Lett., 15, 2905

He, 2022, Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients, J. Cancer Res. Clin. Oncol., 148, 321, 10.1007/s00432-021-03818-w

Travis, 2020, IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy, J. Thorac. Oncol., 15, 709, 10.1016/j.jtho.2020.01.005

Hellmann, 2014, Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint, Lancet Oncol., 15, e42, 10.1016/S1470-2045(13)70334-6

Pataer, 2012, Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy, J. Thorac. Oncol., 7, 825, 10.1097/JTO.0b013e318247504a

C. Blakely, A. Urisman, D. Kerr, W. Wu, B. Bacaltos, J. Rotow, M. Gubens, K. Jones, T. Bivona, Joo SJJoTO: P26. 02 A Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutant non-small cell lung cancer: updated results. 16(10) 2021 S1039-S1040.

W. Kian, L. Roisman, E. Chernomordikov, A. Allen, B. Corn, E. Dudnik, S. Keren, M. Zemel, K. Lavrenkov, Peled NJJoTO. P47. 10 neoadjuvant Osimertinib in EGFR-mutant stage IIIA/B NSCLC-A phase 2 open-label pilot study. 16(10) 2021 S1100.

X. Leng, J. Tang, S. Wang, Y. Wang, P. Li, X. Wei, L. Peng, Q. Fang, Han YJJoTO. P03. 02 Osimertinib as neoadjuvant therapy for resectable EGFR mutant non-small cell lung cancer: a real-world multicenter retrospective study. 16(10) 2021 S979.

Munir, 2021, First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: the glow study, Blood, 138, 70, 10.1182/blood-2021-148666

Huynh, 2021, Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer, Lancet Oncol., 22, 1056, 10.1016/S1470-2045(21)00405-8

Konig, 2022, Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials, ESMO Open, 7, 10.1016/j.esmoop.2022.100455

Raman, 2019, Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer, J. Thorac. Cardiovasc. Surg., 158, 1680, 10.1016/j.jtcvs.2019.08.033

Mirimanoff, 2015, Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?, Chin. Clin. Oncol., 4, 49

Tsuboi, 2021, Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA, Fut. Oncol., 17, 4045, 10.2217/fon-2021-0549

Qu, 2019, Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma, J. Thorac. Oncol., 14, 482, 10.1016/j.jtho.2018.11.017

Liu, 2021, Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer, Mod. Pathol., 34, 1990, 10.1038/s41379-021-00871-1

M. Tsuboi, W. Weder, C. Escriu, C. Blakely, Chaft JJJoTO. P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA 16(3) 2021 S258.

Thông tin
Thông tin xuất bản

Lung Cancer

Tập 178

151-156

Thông tin tác giả